TreeFrog Therapeutics’ C-Stem technology mass-produces high-quality pluripotent stem cells in a 3D environment that mimics the way cells grow in the human body.
Why
Inefficient 2D cell cultivation
Cultivating high-quality, stable pluripotent stem cells in a 2D environment is laborious, difficult, and inefficient.
Not enough pluripotent cells
Workable stem cell therapies will require millions or billions of pluripotent cells for each patient.
Cost of cell therapies
Efficient, mass-production of stable pluripotent stem cells will reduce the cost of therapies for patients.
Market
$8.21bn
Forecast value of the global cell therapy market in 2025, growing at a CAGR of 14.9% from $2.7bn in 2017: Frost and Sullivan
The rest of the content is only available if you are logged in.